Marcello Deraco
马尔切洛·德拉科
MD
Director, Peritoneal Tumors Program; Consultant Surgical Oncologist腹膜肿瘤项目主任；外科肿瘤顾问医师
👥Biography 个人简介
Marcello Deraco directs the Peritoneal Tumours Program at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, which is one of Europe's most experienced CRS + HIPEC centres. He is a world authority on malignant peritoneal mesothelioma, having published the largest Italian series, and has contributed to international consensus on HIPEC for rare peritoneal tumours including sarcomatosis and primary peritoneal carcinoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Malignant Peritoneal Mesothelioma – CRS + HIPEC Outcomes
Accumulated Italy's largest single-centre experience in CRS + HIPEC for malignant peritoneal mesothelioma, demonstrating median survival exceeding 60 months in complete cytoreduction cases and identifying epithelioid histology as the dominant prognostic factor.
Bidirectional Intraperitoneal and Systemic Chemotherapy (BISIC)
Investigated combined intraperitoneal and systemic chemotherapy protocols to enhance tumor penetration prior to CRS, contributing to the development of neoadjuvant intraperitoneal treatment strategies.
HIPEC for Rare Peritoneal Malignancies
Contributed outcome data and consensus guidance for CRS + HIPEC in rare peritoneal tumors including sarcomatosis, desmoplastic small round cell tumors, and primary peritoneal carcinomas, expanding the indications for the combined approach.
Representative Works 代表性著作
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for treatment of malignant peritoneal mesothelioma: a multi-institutional analysis from the PSOGI registry
JAMA Surgery (2016)
International registry study demonstrating that CRS + HIPEC achieves a median survival of 53 months in malignant peritoneal mesothelioma, confirming this as the standard-of-care approach.
Bidirectional chemotherapy and cytoreduction in malignant peritoneal mesothelioma
European Journal of Surgical Oncology (2010)
Prospective trial evaluating combined intraperitoneal + systemic neoadjuvant chemotherapy prior to CRS + HIPEC, demonstrating improved resectability in initially unresectable peritoneal mesothelioma.
Prognostic variables in patients with peritoneal mesothelioma treated with cytoreductive surgery and heated intraperitoneal chemotherapy
Annals of Surgical Oncology (2008)
Identified completeness of cytoreduction, epithelioid histotype, and absence of lymph node metastases as key predictors of survival, guiding patient selection worldwide.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 马尔切洛·德拉科 的研究动态
Follow Marcello Deraco's research updates
留下邮箱，当我们发布与 Marcello Deraco（Fondazione IRCCS Istituto Nazionale dei Tumori, Milan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment